CCL4L2 and COVID-19: Chemokines such as CCL4L2, CCL3, and CCL4 and their respective receptors were also found to be enriched in severe-stage monocytes, indicating the potential of targeting these cytokines and/or their receptors with drugs for treating severe-stage COVID-19 patients.